Primary Biliary Cholangitis: Diagnosis and Treatment

Primary biliary cholangitis is a chronic condition in which the immune system slowly destroys the small bile ducts inside the liver. Bile backs up, damages liver tissue, and over years can lead to scarring. It affects women far more than men, usually appearing between forty and sixty, and it is frequently found on a routine blood test before it has caused any symptoms at all.

It is also one of the clearer examples of a condition where one long-established treatment, taken consistently and started early, substantially changes what happens over the following decades.

🫀 What is actually happening

The liver produces bile, which drains through a branching network of ducts into the intestine, where it helps digest fat and absorb fat-soluble vitamins.

In this condition the immune system attacks the smallest of those ducts, deep within the liver. As they are progressively destroyed, bile cannot drain properly and accumulates — a state called cholestasis. Bile is caustic to liver tissue, so retained bile damages surrounding cells, producing inflammation and, over years, fibrosis. In a minority that fibrosis eventually becomes cirrhosis.

The pace is the important part. This is a slow disease, measured in decades rather than years, and effective treatment slows it further. Many people diagnosed today will have a normal life expectancy and never develop advanced liver disease.

👥 Who it affects

Around nine in ten people with the condition are women, and it typically presents between forty and sixty. It is autoimmune in nature and, like other autoimmune conditions, clusters both in families and within individuals — people with one autoimmune condition are more likely to have another.

Conditions commonly found alongside it:

• Sjogren syndrome — dry eyes and dry mouth, very frequently present and often not connected to the liver diagnosis
• Autoimmune thyroid disease, usually underactive
• Raynaud phenomenon — fingers going white and painful in the cold
• Coeliac disease
• Rheumatoid arthritis and scleroderma

A family history of the condition or of other autoimmune disease raises risk. Environmental factors including smoking and certain infections have been implicated without any single cause being established.

😕 Symptoms

A large proportion of people are diagnosed with no symptoms at all, after a routine blood test shows a raised liver enzyme. Where symptoms occur, two dominate and they are not the ones people expect from a liver condition.

Fatigue affects the majority and is consistently rated the most disabling symptom. It is not proportionate to how advanced the liver disease is — someone with early disease can be profoundly fatigued and someone with more advanced disease can have none — and it does not improve with the main treatment. It is frequently dismissed, both by others and by the person themselves, precisely because the liver tests look reasonable.

Itch affects a large share and can be severe. It is characteristically worse at night and in warm conditions, often affects the palms and soles, and is not accompanied by a rash beyond the marks of scratching. It has its own specific treatments, which are covered below, and it responds poorly to the antihistamines usually offered first.

Other features include dry eyes and mouth, discomfort in the upper right abdomen, and later, as cholestasis advances, yellowing of the skin and eyes, fatty deposits around the eyes and tendons, and darker urine with paler stools.

🧪 How it is diagnosed

Diagnosis is usually straightforward and, importantly, does not require a liver biopsy in most cases.

Two of the following three establish it:

Additional tests define the picture: other liver enzymes, bilirubin, albumin and clotting to assess liver function; imaging to exclude blockage of the larger bile ducts; and specific antibodies where the anti-mitochondrial antibody is negative, since a small proportion have the condition without it.

Non-invasive fibrosis assessment — transient elastography, which measures liver stiffness using a probe on the skin, and blood-based scores — has largely replaced repeated biopsy for tracking how much scarring has developed.

One point worth understanding: a positive anti-mitochondrial antibody with entirely normal liver tests does not mean the person has the condition. Some individuals carry the antibody for years without ever developing it, and monitoring rather than treatment is appropriate in that situation.

💊 Ursodeoxycholic acid

This is the cornerstone of treatment and has been for decades.

Ursodeoxycholic acid is a naturally occurring bile acid, present in small quantities in human bile. Given in therapeutic doses it does several things: it shifts the composition of the bile acid pool toward less toxic acids, it stimulates bile flow, and it protects the cells lining the bile ducts from injury. The effect is to reduce the ongoing damage rather than to suppress the immune attack.

What it achieves, in people who respond:

• Improvement in liver blood tests, usually apparent within months
• Slowed progression of fibrosis
• Delayed need for transplantation, and improved survival

Practical points:

The dose is weight-based, and under-dosing is a recognised reason for apparent non-response. It is worth knowing your own dose relative to your weight.

It is taken indefinitely. The benefit depends on continuous use, and stopping allows the enzymes to rise again within months.

Take it with food, and split the dose across the day where the total is large, which improves both absorption and tolerability.

Separate it from antacids, cholestyramine and other bile acid binders by several hours, since these bind it directly and prevent absorption. This matters particularly because cholestyramine is used for the itch, so someone taking both needs to space them carefully.

Side effects are generally mild — loose stools are the commonest, along with occasional nausea and weight gain, and they frequently settle or respond to dose splitting.

📊 Measuring whether it is working

Response is assessed after around a year using defined criteria based on how far the alkaline phosphatase and bilirubin have fallen. This matters more than it sounds, because response strongly predicts long-term outcome.

People who respond adequately have a life expectancy approaching that of the general population.

People who respond inadequately — roughly a third — face higher risk and are the group for whom additional treatment exists.

Younger age at diagnosis and male sex are both associated with poorer response, which is one reason younger patients are followed more closely.

Second-line options for inadequate responders include obeticholic acid, a modified bile acid that acts on a nuclear receptor regulating bile acid production, and fibrates, which were developed for cholesterol and have shown genuine benefit here. Both are specialist decisions, and obeticholic acid in particular requires careful dosing in advanced disease.

😱 Treating the itch

Cholestatic itch is different from other itch, does not respond well to antihistamines, and has its own treatment sequence that is frequently not applied.

Alongside these: keeping cool, particularly at night; lukewarm rather than hot showers; emollients; cotton clothing and bedding; short nails; and avoiding alcohol, which worsens it.

Sedating antihistamines may help someone sleep through the itch, which is a genuine benefit, but they do not treat the itch itself.

😫 Treating the fatigue

This is harder and honesty helps more than optimism.

Ursodeoxycholic acid does not improve fatigue, and no treatment reliably does. What is worth doing is excluding the contributors that are treatable, because several are common in this population and all get attributed to the liver:

• Underactive thyroid, given the autoimmune overlap
• Anaemia and iron deficiency
• Coeliac disease
• Depression
• Sleep disruption, frequently caused by the itch itself
• Drops in blood pressure on standing, which occur in this condition and cause daytime exhaustion
• Sleep apnoea

Beyond that, pacing, maintaining physical activity within limits, and treating sleep are what remain. The fatigue is real, it is not a measure of how bad the liver disease is, and being believed about it makes a material difference to how people cope with it.

🦴 The complications worth monitoring

Several of these are silent and are found only by looking.

Osteoporosis is considerably commoner in this condition than in the general population, through impaired vitamin D absorption and other mechanisms. Bone density scanning is part of standard care, with calcium and vitamin D supplementation and bone-protecting treatment where indicated. This is covered in the guide to osteoporosis, and the population overlaps almost entirely — women in their fifties.

Fat-soluble vitamin deficiency follows from impaired fat absorption when bile flow is reduced. Vitamins A, D, E and K are checked and replaced where low, and low vitamin K affects clotting.

Raised cholesterol is common and behaves unusually: the pattern seen in cholestasis does not appear to carry the cardiovascular risk that the same numbers would in the general population, and it frequently does not require statin treatment. Cardiovascular risk is still assessed conventionally, but the lipid result alone should not drive treatment.

Portal hypertension can develop, sometimes before cirrhosis is established, and endoscopy to look for varices is done where indicated.

Liver cancer surveillance with six-monthly imaging applies to those with cirrhosis.

Dry eyes and mouth from associated Sjogren syndrome warrant treatment in their own right, including attention to dental health, since reduced saliva causes rapid tooth decay.

🏥 When the liver fails

A minority progress to end-stage liver disease. Liver transplantation works well in this condition, with among the best outcomes of any indication.

Two features are worth knowing. Transplant assessment is triggered not only by liver failure but also by intractable itch, which can be disabling enough to justify it on its own. And the condition can recur in the transplanted liver in some people over years, generally in a milder form and manageable with treatment.

📋 Living with it

Take the treatment consistently. This is the single most important thing, and adherence is the commonest modifiable reason for inadequate response. A slow-moving condition with few symptoms is one people forget to treat.

Attend for monitoring. Blood tests every few months, fibrosis assessment periodically, bone density scanning, and vitamin levels. Much of what matters here is silent and found only by checking.

Avoid alcohol or keep it minimal, since it adds a second insult to a liver already under strain and worsens the itch.

Stop smoking, which is associated with faster progression.

Check medications and supplements before taking anything new, including herbal products, several of which cause liver injury.

Get vaccinated against hepatitis A and B, since additional liver infection is worth avoiding.

Ask specifically about fatigue and itch rather than reporting only what the blood tests show.

🚨 When to seek advice

• New or worsening yellowing of the skin or eyes
• Itch that is severe or preventing sleep — there is a specific treatment sequence for it
• Swelling of the abdomen or ankles
• Vomiting blood or black tarry stools — emergency
• Confusion or unusual drowsiness
• Fever with abdominal pain
• Unexplained bruising or bleeding
• Fatigue that is disabling, which warrants looking for treatable contributors

Ursodeoxycholic acid is stocked as Urso (ursodiol) in the digestive and liver category. It is a long-term prescription requiring weight-based dosing and periodic monitoring of liver tests, and its detailed use is covered in the guide to ursodiol indications and precautions.

❓ Frequently asked questions

📑 Sources and editorial

• EASL clinical practice guidelines on the management of cholestatic liver diseases
• AASLD practice guidance on primary biliary cholangitis
• Joint statement on the change of nomenclature from primary biliary cirrhosis to primary biliary cholangitis
• Evidence on ursodeoxycholic acid and transplant-free survival, and on biochemical response criteria
• Trial evidence for obeticholic acid and for fibrates in inadequate responders
• Guidance on the management of cholestatic pruritus
• Literature on bone disease and fat-soluble vitamin deficiency in chronic cholestasis
• Related reading: ursodiol indications and precautions, osteoporosis
• Related products: digestive and liver category
• RXshop Editorial Team — reviewed by Emily Chen, MD, MPH, Internal Medicine